reverse cell phone numbers mobile sms tracking software android ear spy pro link greene county ohio property information cedar rapids iowa public records people search cell phone number how to find cell numbers


New Scheme for PCSO Medical Assistance for HD & PD Patients

New Scheme for PCSO Medical Assistance for HD & PD Patients

Upon the announcement and implementation of Philhealth Circular No. 022-2015 on August 2015, which increased the benefits of Philhealth members with CKD from 45 to 90 hemodialysis claims, the Individual Medical Assistance Program (IMAP) of the Philippine Charity Sweepstakes Office (PCSO) for Chnronic Kidney Disease (CKD) patients undergoing hemo- and peritoneal dialysis was suspended. On March 11, 2016, the Philippine Charity Sweepstakes Office, invited all dialysis stakeholders to a meeting at their office in the Lung Center of the Philippines to introduce its new IMAP scheme for  dialysis patients.

The new assistance program for Philhealth members emphasized a shift of support from dialysis sessions to medicines (erythropoietin) amounting to P14,000 x 6 claims for a maximum of P84,000 in a year. Non-Philhealth members who avail of the IMAP will get P20,000 for their hemodialysis procedure every other month and P35,000 for dialysis solutions for peritoneal dialysis patients every other month.

Anemia is indeed a very big complication of CKD. The PSN thanks the PCSO for its forsight and consistent support for the plight of CKD patients undergoing dialysis in the country. 

Please see the linked Powerpoint brief for more details.

PCSO IMAP HD and PD Enrolment Program.ppt

DOH alerts public on recalled Meparin 5 & Meparin 25

DOH alerts public on recalled Meparin 5 & Meparin 25

Following the reports of unusually high incidences of chills in several dialysis centers in Manila, Bulacan, Valenzuela and Batangas, the Food & Drug Administration (FDA) after due investigations has issued a recall order on the blood anti-coagulant Meparin 5 and Meparin 25. This brand of Heparin Sodium manufactured by MedChem International Ltd has been found to have been contaminated by an undisclosed bacterial specie. Further investigations on other parenteral products of MedChem are underway.

The Department of Health (DOH) therefore enjoins all hospitals, dialysis centers and clinics to refrain from using Meparin 5 and Meparin 25, and to report to the FDA or DOH any suspicious clustering of symptoms such as the those experienced by the hospitals & dialysis centers in the above-mentioned areas.


Consumers may contact Pharma-Surrey International Inc at telephone number +6324128364, or e-mail at Consumer may also email the FDA at for any question or additional information regarding the product recall.


Related References

Full details of the FDA Advisory